TY - JOUR
T1 - The potential of retinoids for combination therapy of lung cancer
T2 - Updates and future directions
AU - Tripathi, Surya Kant
AU - Pandey, Kamal
AU - Panda, Munmun
AU - Spinella, Michael J.
AU - Rengasamy, Kannan RR
AU - Biswal, Bijesh K.
N1 - Funding Information:
The authors thank (a) MHRD and National Institute of Technology, Rourkela, Odisha, India for providing laboratory and fellowship to Surya Kant Tripathi; (b) Department of Science and Technology, Science and Engineering Research Board (DST, SERB) (Grant Number: ECR/2016/000792 ) for providing fellowship to Munmun Panda; (c) Department of Science and Technology, Odisha, India (Grant number: 1201 ) for providing fellowship to Kamal Pandey and (d) National Institutes of Health grants R01-CA211875 and R03CA223709 and a Reach Grant from the Alex’s Lemonade Stand Foundation to MJS , and (e) Konkuk University, Seoul, South Korea for providing support through KU Brain Pool Program to KRRR.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/9
Y1 - 2019/9
N2 - Lung cancer is the most common cancer-related death worldwide. Natural compounds have shown high biological and pharmaceutical relevance as anticancer agents. Retinoids are natural derivatives of vitamin A having many regulatory functions in the human body, including vision, cellular proliferation and differentiation, and activation of tumour suppressor genes. Retinoic acid (RA) is a highly active retinoid isoform with promising anti-lung cancer activity. The abnormal expression of retinoid receptors is associated with loss of anticancer activities and acquired resistance to RA in lung cancer. The preclinical promise has not translated to the general clinical utility of retinoids for lung cancer patients, especially those with a history of smoking. Newer retinoid nano-formulations and the combinatorial use of retinoids has been associated with lower toxicity and more favorably efficacy in both the preclinical and clinical settings. Here, we highlight epidemiological and clinical therapeutic studies involving retinoids and lung cancer. We also discuss the biological actions of retinoids in lung cancer, which include effects on cancer stem cell differentiation, angiogenesis, metastasis, and proliferative. We suggest that the use of retinoids in combination with conventional and targeted anticancer agents will broaden the utility of these potent anticancer compounds in the lung cancer clinic.
AB - Lung cancer is the most common cancer-related death worldwide. Natural compounds have shown high biological and pharmaceutical relevance as anticancer agents. Retinoids are natural derivatives of vitamin A having many regulatory functions in the human body, including vision, cellular proliferation and differentiation, and activation of tumour suppressor genes. Retinoic acid (RA) is a highly active retinoid isoform with promising anti-lung cancer activity. The abnormal expression of retinoid receptors is associated with loss of anticancer activities and acquired resistance to RA in lung cancer. The preclinical promise has not translated to the general clinical utility of retinoids for lung cancer patients, especially those with a history of smoking. Newer retinoid nano-formulations and the combinatorial use of retinoids has been associated with lower toxicity and more favorably efficacy in both the preclinical and clinical settings. Here, we highlight epidemiological and clinical therapeutic studies involving retinoids and lung cancer. We also discuss the biological actions of retinoids in lung cancer, which include effects on cancer stem cell differentiation, angiogenesis, metastasis, and proliferative. We suggest that the use of retinoids in combination with conventional and targeted anticancer agents will broaden the utility of these potent anticancer compounds in the lung cancer clinic.
KW - Chemoresistance
KW - Combination therapy
KW - Lung cancer
KW - Retinoic acid receptor
KW - Retinoids
UR - http://www.scopus.com/inward/record.url?scp=85068505195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068505195&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2019.104331
DO - 10.1016/j.phrs.2019.104331
M3 - Review article
C2 - 31254665
AN - SCOPUS:85068505195
SN - 1043-6618
VL - 147
JO - Pharmacological Research
JF - Pharmacological Research
M1 - 104331
ER -